Ligand Pharmaceuticals | LGND - Interest Expense On Debt


Ligand Pharmaceuticals reported $1.78M in Interest Expense on Debt for its fiscal quarter ending in December of 2025.





Interest Expense On Debt Change Date
Agenus USD 14.67M 1.35M Mar/2026
Amgen USD 95.64B 94.98B Jun/2026
Anika Therapeutics 183.47M 4.09M Jun/2026
Arrowhead Research USD 24.56M 716K Jun/2026
Baxter International USD 64M 14M Jun/2026
Bristol-Myers Squibb USD 403M 4M Sep/2026
Eli Lilly USD 316M 201.3M Sep/2026
Enanta Pharmaceuticals USD 1.96M 620K Dec/2024
Enviri Corporation USD 28.44M 1.74M Dec/2025
Gilead Sciences USD 269M 22M Sep/2026
GlaxoSmithKline GBP 219M 98M Sep/2026
Glaxosmithkline GBP 192.73M 14.79M Mar/2026
Heron Therapeutics USD 600K 100K Dec/2024
Insmed USD 20.41M 1.57M Sep/2026
Intrexon USD 2K 5K Jun/2024
Ionis Pharmaceuticals USD 18M 1000K Jun/2026
Karyopharm Therapeutics USD 12.55M 66K Mar/2026
Ligand Pharmaceuticals USD 1.78M 875K Dec/2025
MacroGenics USD 4.89M 1.55M Mar/2026
Merck USD 525M 46M Jun/2026
Pacira USD 3.62M 77K Jun/2026
Pfizer USD 667M 4M Jun/2026
Rigel Pharmaceuticals USD 2.06M 31K Sep/2024
Sangamo BioSciences 97.56M 11.39M Jun/2025
Veracyte USD 2K 1000 Dec/2023